Search research articles
Contact Us
Filters
Showing results (91-100 of 115) with videos related to
Page
of 12
Sort By:
Diabetologia
|
August 11, 2019
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
Zien Zhou, Meg Jardine, Vlado Perkovic, et al.
Diabetes Care
|
March 13, 2009
Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study
Stephen M P O'Riordan, Peter Hindmarsh, Nathan R Hill, et al.
JACC. Heart Failure
|
November 3, 2019
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
JingWei Li, Mark Woodward, Vlado Perkovic, et al.
International Journal of Cardiology
|
September 26, 2020
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials
Jie Yu, Zien Zhou, Kenneth W Mahaffey, et al.
Journal of the American Society of Nephrology : JASN
|
July 23, 2020
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program
Megumi Oshima, Bruce Neal, Tadashi Toyama, et al.
Diabetes, Obesity & Metabolism
|
January 26, 2017
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial
Bruce Neal, Vlado Perkovic, David R Matthews, et al.
Circulation
|
March 13, 2018
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Karin Rådholm, Gemma Figtree, Vlado Perkovic, et al.
Journal of the American Society of Nephrology : JASN
|
September 19, 2019
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
June 18, 2015
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
Greg Fulcher, David R Matthews, Vlado Perkovic, et al.
Diabetologia
|
March 15, 2019
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
David R Matthews, Qiang Li, Vlado Perkovic, et al.
Page
of 12
Search research articles
Search
Showing results (91-100 of 115) with videos related to
Sort By:
Page
of 12
Diabetologia
|
August 11, 2019
Canagliflozin and fracture risk in individuals with type 2 diabetes: results from the CANVAS Program
Zien Zhou, Meg Jardine, Vlado Perkovic, et al.
Diabetes Care
|
March 13, 2009
Validation of continuous glucose monitoring in children and adolescents with cystic fibrosis: a prospective cohort study
Stephen M P O'Riordan, Peter Hindmarsh, Nathan R Hill, et al.
JACC. Heart Failure
|
November 3, 2019
Mediators of the Effects of Canagliflozin on Heart Failure in Patients With Type 2 Diabetes
JingWei Li, Mark Woodward, Vlado Perkovic, et al.
International Journal of Cardiology
|
September 26, 2020
An exploration of the heterogeneity in effects of SGLT2 inhibition on cardiovascular and all-cause mortality in the EMPA-REG OUTCOME, CANVAS Program, DECLARE-TIMI 58, and CREDENCE trials
Jie Yu, Zien Zhou, Kenneth W Mahaffey, et al.
Journal of the American Society of Nephrology : JASN
|
July 23, 2020
Different eGFR Decline Thresholds and Renal Effects of Canagliflozin: Data from the CANVAS Program
Megumi Oshima, Bruce Neal, Tadashi Toyama, et al.
Diabetes, Obesity & Metabolism
|
January 26, 2017
Rationale, design and baseline characteristics of the CANagliflozin cardioVascular Assessment Study-Renal (CANVAS-R): A randomized, placebo-controlled trial
Bruce Neal, Vlado Perkovic, David R Matthews, et al.
Circulation
|
March 13, 2018
Canagliflozin and Heart Failure in Type 2 Diabetes Mellitus: Results From the CANVAS Program
Karin Rådholm, Gemma Figtree, Vlado Perkovic, et al.
Journal of the American Society of Nephrology : JASN
|
September 19, 2019
Effect of Canagliflozin on Renal and Cardiovascular Outcomes across Different Levels of Albuminuria: Data from the CANVAS Program
Brendon L Neuen, Toshiaki Ohkuma, Bruce Neal, et al.
Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders
|
June 18, 2015
Efficacy and Safety of Canagliflozin Used in Conjunction with Sulfonylurea in Patients with Type 2 Diabetes Mellitus: A Randomized, Controlled Trial
Greg Fulcher, David R Matthews, Vlado Perkovic, et al.
Diabetologia
|
March 15, 2019
Effects of canagliflozin on amputation risk in type 2 diabetes: the CANVAS Program
David R Matthews, Qiang Li, Vlado Perkovic, et al.
Page
of 12